Title |
Glecaprevir/Pibrentasvir: First Global Approval
|
---|---|
Published in |
Drugs, September 2017
|
DOI | 10.1007/s40265-017-0817-y |
Pubmed ID | |
Authors |
Yvette N. Lamb |
Abstract |
A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; MAVIRET™ (EU); MAVYRET™ (USA)] has been developed by AbbVie. Oral glecaprevir/pibrentasvir 300 mg/120 mg (three 100 mg/40 mg tablets) taken once daily has been approved by the EMA for the treatment of all major genotypes (genotypes 1-6) of chronic HCV infection in adults. It has also been approved by the US FDA for the treatment of adult patients with chronic HCV genotype 1-6 infection without cirrhosis and with compensated cirrhosis, and for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing either an HCV NS5A inhibitor or an NS3/4A PI, but not both. This article summarizes the milestones in the development of glecaprevir/pibrentasvir leading to its first global approval in the EU and subsequent approval in the USA for chronic HCV infection. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 48 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 15 | 31% |
Student > Ph. D. Student | 7 | 15% |
Student > Bachelor | 5 | 10% |
Researcher | 5 | 10% |
Student > Doctoral Student | 4 | 8% |
Other | 2 | 4% |
Unknown | 10 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 23% |
Pharmacology, Toxicology and Pharmaceutical Science | 8 | 17% |
Biochemistry, Genetics and Molecular Biology | 8 | 17% |
Chemistry | 8 | 17% |
Immunology and Microbiology | 2 | 4% |
Other | 2 | 4% |
Unknown | 9 | 19% |